A modeled analysis of the potential impact of pneumococcal conjugate vaccine (PCV) in India estimated that the greatest reductions in deaths due to PCV vaccination would be among the poorest segments of the population. Assuming a vaccination coverage rate of 77% (the current DTP3 coverage rate), PCV would prevent nearly 2.5 times as many deaths per 100,000 children under five in the 2 poorest income quintiles than in the 2 wealthiest groups (313 vs. 134), and nearly 3 times as many deaths per 100,000 if coverage reaches 90% (446 vs. 167).
The model used was specific to the epidemiology, health system situation, and population characteristics of India.
Full Citation:
Megiddo I, Klein E, Laxminarayan R. 2018. Potential impact of introducing the pneumococcal conjugate vaccine into national immunisation programmes: an economic epidemiological analysis using data from India. BMJ Global Health. 3(3).
Title of Article: Potential impact of introducing the pneumococcal conjugate vaccine into national immunisation programmes: an economic epidemiological analysis using data from India
Author(s): Megiddo I, Klein E, Laxminarayan R
Publication Year: 2018
Publication Name: BMJ Global Health
Publication Volume: 3(3)
Publication Source URL: https://pubmed.ncbi.nlm.nih.gov/29765775/
DOI (Digital Object Identifier): 10.1136/bmjgh-2017-000636
Topics: Equity
Disease Vaccines: Pneumococcal disease/PCV/PPSV | Pneumonia
Countries: India
WHO Regions: South-East Asia